Introduction
B cell chronic leukemia is the most common leukemia in the western world, with approximately 10 000 new cases diagnosed each year in the United States. 1 It is characterized by the relentless accumulation in the blood, marrow and lymphoid tissues of mature monoclonal B lymphocytes that express the CD5 surface molecule. The leukemic CLL B cell accumulation appears to be a result of defective apoptosis rather than uncontrolled proliferation. 2 CLL patients suffer immune deficiencies due to impaired humoral immunity characterized by hypogammaglobulinemia. The leukemic B cells express very low levels of surface IgM or IgD, and upon antigen stimulation, are unable to undergo somatic hypermutation and isotype switching. In addition, CLL patients frequently develop autoimmune diseases, suggesting immune dysregulation. 3 Unlike many forms of chronic and acute leukemia, CLL lacks recurrent reciprocal chromosomal translocations and distinctive patterns of oncogene or tumor suppressor gene expression. As a result, it has been difficult to identify the molecular events that lead to the disease phenotypes. CLL-B cells are thought to derive from CD5 + expressing B cells. 2, 4 CD5-expressing normal B cells are a small population of B cells localized at the edge of the germinal center within the mantle zone of the secondary lymphoid follicles. 5 They are considered a good candidate for the normal counterpart of CLL cells because they share several characteristics with the malignant CD5
+ CLL cells. These include the propensity to produce polyreactive, low-affinity IgM autoantibodies and the expression of the cross-reactive idiotypes in the antibody produced. 2, [6] [7] [8] Recently, human memory B cells have been proposed as the normal counterpart of CLL-B cells. 9 However, this alternative model has difficulty accounting for the above features of CLL-B, and the large percentage of CLL cases with leukemic cells having unmutated immunoglubulin gene would argue against an origin of post-germinal center stage cells such as the memory cells. The ideal normal counterpart of CLL will likely remain a subject of discussion. At present, the CD5
+ B cell remains a reasonable candidate as the normal counterpart of CLL and has been used as control cells in many studies of CLL.
One approach to understanding the biological basis of CLL pathophysiology would be to first correlate abnormal gene expression with the disease phenotypes. Recent advances in microarray technology allow for comprehensive profiling of human cancer cells. This technique has been applied successfully in cancer classifications and diagnosis, 10, 11 and in gaining insights into functional pathways. [12] [13] [14] Although expression profiling establishes only a correlative rather than causative role of identified genes in the biological process of the disease studied, experience has shown that the unique and valuable global views of gene expression patterns, when coupled with available knowledge about gene functions, provide the basis for formulating testable hypotheses about the disease pathways. 13, 14 Microarray profiling of hematological malignancy for the purpose of exploring disease pathways instead of disease classification has been reported recently in a study of mantle cell lymphoma (MCL). 15 However, a heterogeneous population of cells was profiled, complicating the interpretation of results and reducing the sensitivity of the study. 15 CLL cells are especially appropriate for microarray analysis because of the relative ease in obtaining a purified, developmentally homogenous leukemic cell population in large quantities. Recently, oligonucleotide microarray has been used to compare the expression patterns of CLL-B cells with several normal B cell populations. 9 That study, however, emphasized sample classification based on the overall expression pattern comparison. It did not focus on analyzing the potential roles of differentially expressed genes in the pathogenesis of CLL. Here, we report the use of oligonucleotide microarrays to compare gene expression profiles between purified CLL-B cells and CD5-expressing normal B cells, and between CLL and normal circulating B cells, as a way to identify potential molecular deregulations that may contribute to the pathophysiology of CLL. The results of our study revealed that in CLL there was significant down-modulation of genes involved in both protein and lipid antigen presentation. We also observed reduced RNA levels for genes involved in interferon gamma response but increased transcript levels for IL-4 response genes. The profile also indicated reduced cell proliferation and metabolism but increased intracellular protein transport and processing, as well as increased production of extracellular matrix and adhesion molecules in CLL-B cells relative to normal CD5 + B cells. The significance of these abnormal gene expression patterns to CLL pathobiology is discussed.
Materials and methods

Cell isolation and RNA extraction
Normal CD5
+ B cells were purified from four fresh human tonsils collected from routine tonsillectomy procedures. CD5 + B cells like these were routinely used in most laboratories as the normal controls in the studies of CLL-B cells. The tonsil tissues were disrupted by gentle mechanical means, and the resulting cell suspension was centrifuged through FicollHypaque to obtain mononuclear cells. T cells were removed by two rounds of rosetting with an excess amount of fresh, neuroaminidase-treated sheep red blood cells (SRBC). Less than 1% of the remaining cells were CD2 + after rosetting. The cells were then incubated with anti-CD5 MAb (Caltag, Burlingame, CA, USA) for 3-5 h at 4ºC, washed thoroughly in PBS and incubated for 12 h at 4ºC with 20-fold excess (relative to target cells) of the magnetic beads coated with goat antiIgG (Dynal, Lake Success, NY, USA). CD5
+ B cells attached to the beads were then magnetically separated from the remaining cell suspension. After isolation, the CD5 + B cells on beads were directly lysed with Trizol (Gibco, Carlsbad, CA, USA) for total RNA extraction.
Heparinized venous blood samples from eight CLL patients with Rai stages varying from 0 to 2 (Table 1) were obtained after written informed consent. None of the CLL patients received chemotherapy treatment during the 6 months prior to the blood drawn for this study. Mononuclear cells were obtained after centrifugation over Ficoll-Hypaque, and CLL cells from all but two samples were negatively selected by depleting T cells using two rounds of anti-CD2 coated magnetic beads (Dynal). More than 96% of the purified CLL cells were CD19
+ and CD5 + in the CLL samples studies. Freshly isolated CLL cells were immediately lysed in Trizol for total RNA extraction.
For two of the CLL samples (CM and C72), additional steps of anti-CD5 coating followed by positive selection using mag- The use of all patient and normal samples above were according to an IRB approved protocol.
GeneChip array expression analysis
Poly(A)
+ RNA was selected using Oligotex mRNA midi kits (Qiagen, Valencia, CA, USA). Double-stranded cDNA was synthesized from poly(A)
+ RNA with the SuperScript Choice kit (Gibco) and oligo(dT) primers that contained a T7 RNA polymerase recognition sequence at the 5Ј end. Approximately 1 g of cDNA was subjected to in vitro transcription in the presence of biotinylated UTP and CTP (Enzo Diagnostic, Farmingdale, NY, USA) using the MegaScript T7 kit (Ambion, Austin, TX, USA). The labeled cRNA was fragmented and hybridized to a set of four oligonucleotide arrays (GeneChip Hu6000 array set; Affymetrix) overnight. The arrays were then washed, stained with phycoerythrin-streptavidin and scanned according to the manufacturer's instructions. The array contains 6790 probe sets for 6416 genes (5223 known human genes and 1193 unnamed ESTs). Expression data were analyzed using GeneChip 3.0 software (Affymetrix, Santa Clara, CA, USA). Global scaling of intensity values was used. The average intensity over all genes on a chip was adjusted to 116 for all arrays to compensate for array-related variations in hybridization efficiency and signal acquisition. Fluorescence intensity levels of less than 20 units (after scaling) were converted to 20, since discrimination of expression below this level could not be performed with confidence. For each gene, the CLL/TB5 + expression ratio is calculated from the absolute expression value of one of the eight CLL samples and one of the four tonsilar CD5 + B cell samples. The average expression ratio (Avg(CLL/TB5 + )) was calculated by averaging the 32 possible CLL/TB5 + expression ratios.
Northern blot analysis
One microgram of polyA + RNA from purified tonsillar, peripheral blood, and CLL B cells was separated on a 1% agarose gel containing 0.6 M formaldehyde, transferred on to a nylon membrane (Nytran; Schleicher and Schuell, Keene, NH, USA), and hybridized with DNA probes randomly primed with 32 PdCTP. Hybridization signals were detected using a PhosphoImager (Molecular Dynamics, Sunnyvale, CA, USA).
Results and discussion
Quality control of samples
To investigate the molecular basis underlying the different phenotypes of normal and CLL-B cells, we profiled the expression of 6500 independent genes in freshly isolated leukemic B cell samples from eight CLL patients (Table 1) , as well as purified control B cell samples. The control B cell samples included four tonsillar CD5 + B cell samples and one pooled peripheral blood CD19 + B cell sample. Some genes with previously characterized expression in CLL were included in the array and were used as internal controls. The expression levels of these genes are summarized in Figure 1 . As expected, tonsil CD5
+ cells and CLL cells expressed high levels of the mRNA for the IgM heavy chain. Indicative of the monoclonal nature of the disease, there was predominance in CLL cells of one of the two Ig light chains (lambda or kappa) expression that was consistent with available clinical phenotyping results (data not shown). CD4 expression was not detectable (mean expression intensity (same below): 22 for CLL vs 24 for tonsil CD5
+ cells), indicating little or no contamination with T cells in the preparations. Expressions of CD3 and CD14 mRNA were low with similar levels between normal and CLL samples (CD3: 63 for CLL vs 75 for tonsil CD5 + cells; CD14: 59 for CLL vs 55 for tonsil CD5 + cells). CD23, a molecule commonly associated with CLL, 16 was highly expressed in CLL samples, while on average, CD23 expression in tonsillar CD5
+ B cells was lower (2318 for CLL vs 1059 for tonsil CD5 + cells). As reported previously, 2 there was an increase in the level of bcl-2 mRNA, but no abnormal expression of p53 or Rb in CLL relative to normal CD5
+ cells ( Figure 1 ). The results described above indicate little degradation or contamination of our mRNA samples and demonstrate the robustness of the sample purification procedure.
Global pattern of gene expression
To identify patterns of gene expression in CLL that differed from those in normal control CD5
+ B cells, we first employed a self-organizing map (SOM) algorithm to analyze the 12 samples (four tonsillar CD5
+ normal control and eight CLL
Figure 1
Expression of control genes. Expression levels of selected genes in four tonsilar CD5 + B samples (triangles) and eight CLL-B samples (circles) studied. Expression levels of less than 20 are converted to 20.
Leukemia samples), using the program GeneCluster as previously described. 13 The SOM algorithm, like other clustering algorithms, serves to expose patterns in the gene expression data without using prior knowledge. The expression levels of the 6790 probe sets represented on the GeneChip arrays were used in the analysis. The default variation filter in the program was used to eliminate genes that did not change significantly across samples. SOM was used to organize the remaining genes into 18 clusters (Figure 2 ). Although these clusters were generated without presumptions, they corresponded to clear biological relevance. For example cluster c7 identified 113 genes that were consistently up-regulated in CLL-B cells and cluster c16 identified 148 genes consistently down-regulated in CLL. Most of the remaining clusters represent genes that were preferentially expressed in only one of the samples examined, thus capturing the unique signature pattern of the sample (eg cluster c1, c4 and c8). The lack of clusters representing genes differentially expressed in only those two positively selected CLL samples (C72 and CM) indicated that under our experimental conditions, additional positive selection based on CD5 ligation of CLL cells had little effect on the overall gene expression pattern in CLL. SOM analysis of gene expression in normal and CLL-B cells. Using GeneCluster, 13 the 1958 genes that passed the default variation filter were grouped into 18 clusters. Each cluster is represented by the average expression pattern for genes in the cluster. Normalized averaged expression levels are shown on the y-axis, with the two lines delineating 1 s.d. off the average. The 12 samples are represented on the x-axis, with the order being (from left to right) T1, T2, T3, T62, C101, C1010, C117, C72, C725, C828, CH and CM. The first four samples from the left are the tonsillar CD5 + B cells and the remaining eight CLL samples. The number of genes in each cluster is indicated at the top center of each cluster. Note that the cluster c7 represents 113 genes that showed up-regulation in all CLL samples and cluster c16 consists of 148 genes that were down-regulated in all CLL samples. Most other clusters, such as c8, consist of genes that were preferentially expressed in only one of the samples examined.
Leukemia
Differentially expressed genes between CLL and normal CD5
+ B cells
To represent quantitatively the gene expression differences between normal and CLL cells, for each gene we obtained an average expression ratio in each CLL sample, ie average of the four possible CLL/TB5 + ratio values from the CLL and four TB5
+ expression values. We first selected for genes that showed two-fold or more differential expression between normal and CLL cells in at least six of the eight CLL samples. We then used a hierarchical clustering program (Cluster 17 ) to cluster these differentially expressed genes. Among the 248 genes used in hierarchical clustering, 56 were excluded for further analysis due to low signal intensity (average of CLL and average of TB5 + both Ͻ100) or inconsistent expression pattern (coefficient of variation for CLL/TB5
+ ratios more than 100%), leaving 192 differentially expressed genes. Northern analysis of 10 randomly selected genes from the 192 genes all confirmed the results from the GeneChip hybridization (two shown in Figure 3 ). Among these 192 genes, about half (104 genes) were expressed in the normal peripheral blood B cells at a level not significantly different (less than two-fold) to the average expression level in the eight CLL samples. These 104 genes, although differentially expressed between tonsillar CD5
+ B cells and circulating CLL cells, may contain genes related to the different anatomical locations of the two lymphocyte populations (circulating vs non-circulating) and were thus excluded for further consideration. Some of these 104 genes, for example a cluster of 19 down-regulated genes known to be involved in various aspects of cell proliferation, may account for some of the phenotypes of CLL-B (eg cell cycle arrest in CLL). They were nonetheless excluded, due to a similar expression pattern in the normal peripheral B cells, which were also non-cycling. The remaining 88 genes are likely to be an underestimate of genes differentially expressed between normal CD5 + B cells and CLL cells. The age distributions of our tonsil, normal blood, CLL blood samples are non-overlapping, with average age increasing in that order. There are 19 genes in the list of 88 with expression level in normal blood falling between average levels in tonsil and in CLL. Among them, one gene (interferon receptor ifnar2-1) showed significant correlation between expression level in CLL patient and patient age (absolute value of correlation coefficient Ͼ0.7) and is excluded from the final list.
The remaining 87 genes included 51 genes that were upregulated and 36 genes that were down-regulated in CLL cells compared to normal CD5 + B cells. The complete list of these genes is shown in Table 2 . The average expression levels together with their standard deviations in tonsil and CLL samples, as well as the average CLL/TB5 + ratios, are listed in Table 2 . Their expressions in the pooled normal B cell sample are also included for reference. These genes could be grouped into different functional categories (Table 2) . Overall, about one-third of differentially expressed genes appeared to be related to immunoregulation, suggesting that the immune deregulation was the most prominent abnormality of CLL. Some of the genes showing the most prominent differences are described below.
CD1 gene family
CLL cells display the characteristics of anergic B cells that are defective in presenting antigens and mounting antibody responses to antigen. 18, 19 We observed down-regulation of B cell surface molecules that are believed to be critical in T-B cell interaction, such as CD40 and CD83. 20 The costimulatory molecule CD27, whose expression in B cells is suppressed by CD40, 21 was up-regulated as expected. Surprisingly, the two most down-regulated genes (25-fold and five-fold suppression, respectively) were CD1c and CD1d, two members of the CD1 family of MHC-like molecules responsible for presenting lipid rather than peptide antigen to T cells. 22 In CLL-B cells these two CD1 mRNAs were virtually undetectable ( Table 2) . Unique among MHC and MHC-like molecules, CD1 is recognized by the antigen receptors of two prominent T cell subset with innate immune function: the CD 1d-restricted human Valpha24 natural killer T cell and the CD1c-specific human V␦1 gamma delta T cells. 22 Thus, our data indicate for the first time that the innate immunity mediated by the activation of CD1-restricted T cells may be compromised in CLL.
The activation of NK T cells results in engagement of NK T cell TCR and the lysis of microbial-infected antigen-presenting cells. Given that leukemic B cells are the major antigen presenting cells in CLL, lack of CD1 expression on CLL-B may explain the increased chance of microbial infection in CLL patients. However, more importantly, activation of NK T cells in vivo also induces a series of cellular activation events that leads to the activation of innate cells and adaptive cells such as B cells and T cells. 22, 23 Thus, defective CD1-restricted T cell activation conceivably can also lead to reduced adaptive response in CLL. Consistent with this hypothesis, CD69, which upon CD1-restricted T cell activation is induced on normal B cells, 23 was expressed five-fold lower in CLL-B cells than in normal cells ( Table 2 ). Given that CD1-restricted T cells play critical roles not only in microbial immunity, but also in autoimmune regulation 24 and tumor prevention, 25 it would be of great interest to study the status of T cells that recognize the CD1 molecules in CLL patients.
Abnormal expression of genes involved in cytokine response
In the category of cytokine signaling, the receptor for interleukin 4, IL-4R, is up-regulated by more than five-fold. IL-4 has been shown to protect CLL-B cells from spontaneous [26] [27] [28] and Fas-mediated 29 apoptosis in vitro. The potential increase in IL-4 levels in T cells from CLL patients [30] [31] [32] would further exacerbate the IL-4 induced response of CLL cells. Increased IL-4 33 and this function of IFN-gamma is achieved primarily through direct action on the tumor cells to increase their immunogenicity. 34, 35 The major consequence of reduced IFN-gamma signaling in CLL may be decreased susceptibility of CLL cells to tumor immunity and thus increased CLL-B survival. The genes are listed in putative functional categories and within each category are sorted by fold changes (Avd(CLL/TB5 + )). BB, normal peripheral CD19 + cells pooled from seven individuals.
Increased expression of immunoglobulin receptors
We also observed induction of several immunoglobulin receptor messages in CLL-B cells. These include the neonatal IgG receptor FcRn (5.7-fold increase), the Fc-epsilon receptor CD23 (2.8-fold increase) and the low affinity IgG Fc receptor FcGR2B (2.4-fold increase). The overexpression of CD23 is consistent with increased response to IL-4, as CD23 can be induced by IL-4 in vitro in both normal B cells and CLL-B.
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FcGR2B was recently shown to be the target for deregulation by chromosomal translocation in B cell follicular lymphoma, and overexpression of FcGR2B may play a role in tumor progression in follicular lymphoma. 36 Increased FcGR2B engagement may reduce antibody-dependent cellmediated cytotoxicity of antibodies against tumor cells in vivo, 37 therefore it is likely that increased FcGR2B also contributes to the survival of leukemic cells. The observation of increased FcGR2B expression in CLL should be relevant to the treatment of CLL as several antibody therapeutics, including rituximab (anti-CD20) and CAMPATH (anti-CD52), are currently in clinical trials for treatment of CLL.
Increased expression of the extracellular matrix proteins
It is surprising that CLL cells strongly up-regulate several extracellular matrix proteins. The most highly induced gene in this category is fibromodulin, with 21.5-fold induction in CLL. Fibromodulin is a proteoglycan that interacts with the type I and II collagen fibrils in the extracellular matrix and has a role in the assembly of collagen fibrils in connective tissues. 38 Also overexpressed in CLL-B cells is the type IX collagen, a fibrilassociated collagen with similar function to fibromodulin. 39 Corresponding to increased expression of these matrix proteins, there is decreased expression of collagenase V involved in the degradation of extracellular matrix. These together with the increased expression of P-selectin ligand, agrin, and integrin beta7 suggest increased adhesiveness and reduced mobility of CLL cells relative to normal counterparts. This is particularly noteworthy given that the CLL-B cells are circulating whereas the CD5 + normal counterparts for this study are cells in tissue. Most of these molecules were not overexpressed in normal circulating B cells ( Table 2 ). The contribution of these phenotypic changes to the characteristics of CLL cell trafficking remains to be determined. There was no correlation, however, between the expression of these molecules and the degree of leukemic infiltration of lymphoid organs in our patients.
The interactions between cancer cells and tissue microenvironment are critical for cancer survival and progression. 40 For example, interaction with fibronectin prevents CLL-B from apoptosis. 41 It is not clear with what cell types the CLL-B cells may have increased contact. One possible candidate could be the bone marrow stromal cells, which adhere to CLL cells but not normal B cells and provide survival factors for CLL. 42, 43 The increased expression of chemokine receptor CCR7 (Figure 3) is noteworthy, as the role of this receptor on the B cells is not primarily for B cell homing to lymph organs, 44, 45 but rather for bringing T cells and activated B cells within lymph organs together for interaction. 45 CLL-B cells express CCR7 at a level similar to activated normal B cells (unpublished observation). Being the major accessory cells in CLL, the leukemic cells may compete with competent, activated B cells for T cell interaction. 46 Moreover, once in contact, CLL-B cells quickly inactivate T cells by downregulating CD40L and costimulatory molecules on the T cell surface, 47, 48 rendering T cells anergic. Further study is needed to elucidate the role of CCR7 in CLL pathogenesis. The expression of agrin in CLL-B cells, but not normal B cells, is also unusual. When secreted from T cells agrin can promote the formation of the contact site (immunological synapse) between activated T cells and antigen-presenting cells. 49, 50 It will be of interest to test whether agrin from CLL-B cells has a similar function in promoting immunological synapse formation, or in clustering molecules on CLL-B cells to form contact site with other cell types.
Changes in non-immune-related gene expression
The comprehensive nature of microarray gene expression profiling allows one to gain valuable insights beyond immune Leukemia deregulation. For example, several genes involved in cellular proliferation pathways were also identified in the differentially regulated set. Most of the identified proliferative protooncogenes (c-MYC, Jun-B, c-Fos, Hox-A10, BCL-6, G2-specific Cyclin B2) were down-regulated, while inhibitor for proliferation (Id3) was over expressed. This pattern is expected given the cell cycle arrest phenotype of CLL-B cells. Consistent with the quiescent state of CLL-B cells, many genes involved in cellular metabolism (such as aldehyde dehydrogenase 2) were down-regulated (Table 2) .
It should be noted that although c-Myc is the primary transcriptional factor that regulates proliferation in many tumor cell types, it is not clear whether its down-regulation is the cause for the growth arrest in CLL. Many c-Myc target genes have been identified 51 and are represented in our array. However, they were not significantly down-regulated in CLL (data not shown). In addition, the c-Myc partner Max expression was not significantly decreased relative to CD5 + B cells (average fold change = 0.70).
The transcriptional factor dbpA was highly induced in CLL (average 15-fold) relative to CD5 + B cells. Moreover, the high expressions were specific to CLL as they were not significantly up-regulated in purified CD5
+ B cells from a MCL patient (unpublished observation). A closely related protein dbpB (YB1) was highly but not differentially expressed in CLL (average fold change = 0.76), indicating the specificity of dbpA overexpression. As a DNA binding protein containing the cold-shock domain, dbpA is known to inhibit the induction of MHC molecules by IFN-gamma, 52 but it has never been described in human B cells. It will be of interest to investigate the potential role of this transcriptional regulator in pathogenesis of CLL.
Although there are at least 25 genes on our GeneChip with known roles in apoptosis, we found only three anti-apoptotic molecules differentially expressed in CLL. In addition to Bcl2, the anti-apopototic molecule DAD-1 was overexpressed in CLL cells by about three-fold. DAD-1 does not belong to the Bcl2 family and it protects cells from apoptosis by mechanisms distinct from those used by bcl-2. 53 Paradoxically, the Bcl2 family antiapoptotic molecule A1 was decreased in CLL. While the Bcl-2 family of proteins plays a major role in protecting CLL-B cells from apoptosis induced by therapeutic agents, 54 it is not clear whether they are critical in establishing the pro-survival phenotype of CLL in vivo, since prior to therapy CLL cells do not encounter those therapeutic agents. In fact, when cultured in vitro, CLL-B cells, even with overexpression of Bcl2, are more prone to spontaneous apoptosis than normal peripheral blood B cells or CD5
+ normal B cells. 42 This observation suggests the increased steady-state level of antiapoptotic molecules, while important in determining response to therapy, is not sufficient to explain the CLL pathogenesis.
Finally, we found in CLL cells significant up-regulation of genes for protein processing (N-acetylglucosaminyltransferase 1, PCBD, beta-galactoside alpha-2,6-sialyltransferase) and protein trafficking/transport (p63, ABC-1, phosphatidylethanolamine binding protein, syntaxin 5A). Among them, the p63 mRNA, for a transmembrane protein localized to the ER-Golgi intermediate compartment, 55 shows a 48-fold increase, the highest in the entire list. Few studies have explored the role of intracellular protein processing and transport in the disease phenotype of CLL. Our results correlate the deregulation of this process with CLL. Some proteins encoded by genes identified here may modulate functions of immunoregulatory proteins. For example, beta-galactoside alpha 2,6-sialyltransfer-ase sialylates CD22 and can abrogate CD22-mediated B lymphocyte adhesion in vitro. 56 Identifying specific protein processing and trafficking pathways that are affected, and the target molecules that they regulate, will help understand the pathogenesis of the disease.
CLL is a complex human disease characterized by abnormal cell death rather than increased proliferation. Our comprehensive gene expression profiling provides important information on the global pattern of gene expression in CLL and identifies many candidate genes potentially involved in CLL pathology. The physiological phenotype of CLL predicts deregulation of a number of genes that were identified in our study, for example, the down-regulation of genes involved in T-B cell interaction and in cell proliferation. More importantly, however, our study revealed several unexpected patterns of gene expression in CLL that may shed new light on the disease mechanisms. These include the suppression of CD1c and CD1d involved in innate immunity, the reduced IFN-gamma signaling, increased adhesiveness, as well as increased intracellular protein trafficking and processing. The prolonged survival of CLL-B cells may not only be due to increased expression of anti-apoptotic molecules, but also through increased response to survival factors, characterized by increased response to IL-4 and adhesion to extracellular matrix, and through various mechanisms of evading the immune response, for example, by turning off the expression of CD1c and CD1d, reducing the immunogenic response to interferon gamma, inactivating T cell in B-T interaction and increasing the expression of immunoglobulin receptors which neutralize antibody-dependent cell-mediated cytotoxicity. The changes in these cellular phenotypes likely result from abnormal transcriptional regulation, for which we identified a highly abnormally expressed transcriptional factor dbpA, and from abnormal post-transcriptional regulation, where significantly altered intracellular protein processing and trafficking seems apparent. Our results provide a valuable basis for additional, more directed and focused studies on CLL pathobiology.
